[A24-31] Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101
Last updated 02.05.2024
Project no.:
A24-31
Commission:
Commission awarded on 18.03.2024 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Head and nerves
Indication:
Adults with neovascular (wet) age-related macular degeneration
Result of dossier assessment:
After addendum now: indication of minor added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A24-31_en
| Project no. | Title | Status |
|---|---|---|
| A23-101 | Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.